Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: An open-label multicenter study

Tempei Otsubo, Yoshinori Watanabe, Seiji Hongo, Mikichika Inoue, Kimiko Akimoto, Ken Murakami, Ryutaro Takahashi, Toshiaki Kikuchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). Patients and methods: A total of 113 outpatients with MDD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and treated with a stable dose of IR paroxetine for at least 6 months were enrolled. Patients were then switched to CR paroxetine for 8 weeks. Effectiveness was evaluated by scores on the Himorogi Self-Rating Depression/Anxiety Scales (HSDS/HSAS) and the Clinical Global Impression – Severity (CGI-S). Safety was evaluated based on the reported adverse drug reactions (ADRs). Medication satisfaction and preference were assessed based on questionnaire responses using Likert-type scales. Results: The overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (P<0.001). Furthermore, CR paroxetine was superior to IR paroxetine (P<0.001) according to the results of the CGI-S evaluation. ADRs were experienced by 14 (12.4%) patients, including dry mouth, nausea/vomiting, somnolence/drowsiness, and wakefulness/arousal during sleep. Satisfaction and preference for paroxetine improved after switching to the CR formulation (P<0.001; chi-square test). Conclusion: These results suggest that switching the treatment from IR to CR paroxetine could improve depressive symptoms and decrease ADRs. However, these results may have been caused by the psychological effect of drug switching. Hence, future studies with blinded evaluation methods are required to confirm and expand our findings.

Original languageEnglish
Pages (from-to)955-966
Number of pages12
JournalNeuropsychiatric Disease and Treatment
Volume14
DOIs
Publication statusPublished - 2018 Apr 6

Fingerprint

Paroxetine
Major Depressive Disorder
Multicenter Studies
Drug-Related Side Effects and Adverse Reactions
Therapeutics
Drug Substitution
Depression
Safety
Wakefulness
Sleep Stages
Chi-Square Distribution
Arousal
Diagnostic and Statistical Manual of Mental Disorders
Nausea
Antidepressive Agents
Vomiting
Mouth
Sleep
Outpatients
Anxiety

Keywords

  • Antidepressant
  • Controlled-release paroxetine
  • Depression
  • Drug formulation
  • Immediate-release

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder : An open-label multicenter study. / Otsubo, Tempei; Watanabe, Yoshinori; Hongo, Seiji; Inoue, Mikichika; Akimoto, Kimiko; Murakami, Ken; Takahashi, Ryutaro; Kikuchi, Toshiaki.

In: Neuropsychiatric Disease and Treatment, Vol. 14, 06.04.2018, p. 955-966.

Research output: Contribution to journalArticle

Otsubo, Tempei ; Watanabe, Yoshinori ; Hongo, Seiji ; Inoue, Mikichika ; Akimoto, Kimiko ; Murakami, Ken ; Takahashi, Ryutaro ; Kikuchi, Toshiaki. / Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder : An open-label multicenter study. In: Neuropsychiatric Disease and Treatment. 2018 ; Vol. 14. pp. 955-966.
@article{80028937b47d42fb92c9def60334a41e,
title = "Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: An open-label multicenter study",
abstract = "Aim: To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). Patients and methods: A total of 113 outpatients with MDD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and treated with a stable dose of IR paroxetine for at least 6 months were enrolled. Patients were then switched to CR paroxetine for 8 weeks. Effectiveness was evaluated by scores on the Himorogi Self-Rating Depression/Anxiety Scales (HSDS/HSAS) and the Clinical Global Impression – Severity (CGI-S). Safety was evaluated based on the reported adverse drug reactions (ADRs). Medication satisfaction and preference were assessed based on questionnaire responses using Likert-type scales. Results: The overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (P<0.001). Furthermore, CR paroxetine was superior to IR paroxetine (P<0.001) according to the results of the CGI-S evaluation. ADRs were experienced by 14 (12.4{\%}) patients, including dry mouth, nausea/vomiting, somnolence/drowsiness, and wakefulness/arousal during sleep. Satisfaction and preference for paroxetine improved after switching to the CR formulation (P<0.001; chi-square test). Conclusion: These results suggest that switching the treatment from IR to CR paroxetine could improve depressive symptoms and decrease ADRs. However, these results may have been caused by the psychological effect of drug switching. Hence, future studies with blinded evaluation methods are required to confirm and expand our findings.",
keywords = "Antidepressant, Controlled-release paroxetine, Depression, Drug formulation, Immediate-release",
author = "Tempei Otsubo and Yoshinori Watanabe and Seiji Hongo and Mikichika Inoue and Kimiko Akimoto and Ken Murakami and Ryutaro Takahashi and Toshiaki Kikuchi",
year = "2018",
month = "4",
day = "6",
doi = "10.2147/NDT.S152985",
language = "English",
volume = "14",
pages = "955--966",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder

T2 - An open-label multicenter study

AU - Otsubo, Tempei

AU - Watanabe, Yoshinori

AU - Hongo, Seiji

AU - Inoue, Mikichika

AU - Akimoto, Kimiko

AU - Murakami, Ken

AU - Takahashi, Ryutaro

AU - Kikuchi, Toshiaki

PY - 2018/4/6

Y1 - 2018/4/6

N2 - Aim: To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). Patients and methods: A total of 113 outpatients with MDD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and treated with a stable dose of IR paroxetine for at least 6 months were enrolled. Patients were then switched to CR paroxetine for 8 weeks. Effectiveness was evaluated by scores on the Himorogi Self-Rating Depression/Anxiety Scales (HSDS/HSAS) and the Clinical Global Impression – Severity (CGI-S). Safety was evaluated based on the reported adverse drug reactions (ADRs). Medication satisfaction and preference were assessed based on questionnaire responses using Likert-type scales. Results: The overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (P<0.001). Furthermore, CR paroxetine was superior to IR paroxetine (P<0.001) according to the results of the CGI-S evaluation. ADRs were experienced by 14 (12.4%) patients, including dry mouth, nausea/vomiting, somnolence/drowsiness, and wakefulness/arousal during sleep. Satisfaction and preference for paroxetine improved after switching to the CR formulation (P<0.001; chi-square test). Conclusion: These results suggest that switching the treatment from IR to CR paroxetine could improve depressive symptoms and decrease ADRs. However, these results may have been caused by the psychological effect of drug switching. Hence, future studies with blinded evaluation methods are required to confirm and expand our findings.

AB - Aim: To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). Patients and methods: A total of 113 outpatients with MDD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and treated with a stable dose of IR paroxetine for at least 6 months were enrolled. Patients were then switched to CR paroxetine for 8 weeks. Effectiveness was evaluated by scores on the Himorogi Self-Rating Depression/Anxiety Scales (HSDS/HSAS) and the Clinical Global Impression – Severity (CGI-S). Safety was evaluated based on the reported adverse drug reactions (ADRs). Medication satisfaction and preference were assessed based on questionnaire responses using Likert-type scales. Results: The overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (P<0.001). Furthermore, CR paroxetine was superior to IR paroxetine (P<0.001) according to the results of the CGI-S evaluation. ADRs were experienced by 14 (12.4%) patients, including dry mouth, nausea/vomiting, somnolence/drowsiness, and wakefulness/arousal during sleep. Satisfaction and preference for paroxetine improved after switching to the CR formulation (P<0.001; chi-square test). Conclusion: These results suggest that switching the treatment from IR to CR paroxetine could improve depressive symptoms and decrease ADRs. However, these results may have been caused by the psychological effect of drug switching. Hence, future studies with blinded evaluation methods are required to confirm and expand our findings.

KW - Antidepressant

KW - Controlled-release paroxetine

KW - Depression

KW - Drug formulation

KW - Immediate-release

UR - http://www.scopus.com/inward/record.url?scp=85045506781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045506781&partnerID=8YFLogxK

U2 - 10.2147/NDT.S152985

DO - 10.2147/NDT.S152985

M3 - Article

AN - SCOPUS:85045506781

VL - 14

SP - 955

EP - 966

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -